AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

Anthropic in October last year iterated its Claude AI model to better cater to biopharma purposes. Sanofi, Novo Nordisk, ...

NSG Bio announced the signing of a Memorandum of Understanding (MOU) with Charles River Laboratories ("Charles River"), marking a new collaboration aimed at strengthening support for biotech companies ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...